N/A
Completed N=77
Complement and Cardiovascular Risk in Adolescents
Source: ClinicalTrials.gov NCT02821104 ↗Enrolled (actual)
77
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcomePrimary: Complement C3 Genotype — 22; 45; 2; 6 Participants
Summary
This study evaluates how genetic variations in complement, a part of the immune system, affect cardiovascular risk in adolescents.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Complement C3 Genotype |
22; 45; 2; 6 | — |
| PRIMARY C4 Copy Number |
14; 35; 15; 6; 5; 0 | — |
| SECONDARY BMI |
22.0 | — |
| SECONDARY Waist Circumference |
72.5 | — |
| SECONDARY Body Fat |
23.9 | — |
| SECONDARY Endothelial Function |
-81.7 | — |
| SECONDARY Vascular Stiffness |
-3.3 | — |
| SECONDARY Endothelin 1 |
2.06 | — |
| SECONDARY Inflammation |
0.68 | — |
| SECONDARY Clotting |
3.78 | — |
| SECONDARY Insulin Sensitivity |
4.25 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy adolescents age 12 to 18 years
- Medication free for 2 weeks except oral contraceptives in females
- Non Hispanic white
Exclusion Criteria
- Chronic medications except for contraceptives in females.
- History of autoimmune disease either endocrine or connective tissue type
- History of hematologic or renal disease, malignancy or other chronic disease
- Hispanic ethnicity,
- African-American or Asian race
Data sourced from ClinicalTrials.gov (NCT02821104). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.